Antidepressants are commonly used in dementia. Depression is a frequent and important co-morbidity in dementia, and antidepressants are often used to treat depression and more widely. However, there are questions about their utility in depression in dementia and other behavioural and psychological symptoms of dementia. The aim of this narrative review is to summarize the evidence on whether there is therapeutic value in prescribing antidepressants to people with dementia. Login using your SSSFT NHS OpenAthens for full text. SSOTP - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Despite the fact that today most of the patients with psychological disturbances assume some form of psychotropic drug treatment, clinical psychologists may have little familiarity with psychopharmacology and are substantially unaware of subtle and yet pervasive potential effects of medications in clinical presentations. In their training, psychologists are generally exposed, at best, to some general principles of drug action. Standard psychopharmacology textbooks tend to omit the subtle psychological changes that may occur during psychotropic drug treatment. To read the full article, log in using your SSSFT NHS OpenAthens details. SSOTP - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
You have a duty of candour if you make a professional error. Here’s how to handle the situation. To read the full article, log in using your MPFT NHS OpenAthens details.
In the most exhaustive investigation to date—an important contribution because of its broad scope and methodological rigour—Toshi A Furukawa and colleagues1 report findings that resonate well with earlier efforts: selective serotonin reuptake inhibitors (SSRIs) display dose-dependent beneficial effects up to the low-to-medium end of their licensed doses,2, 3, 4 and so do mirtazapine and venlafaxine. Offsetting this beneficial effect is the well-known increase in dropouts due to side-effects, which comes with higher doses.1, 2, 3 On balance, Furukawa and colleagues conclude that the lower range of licensed doses is likely to yield the best (achievable) balance between efficacy, tolerability, and acceptability.1 . Please contact the library to request a copy of this article - http://bit.ly/2HjNDf3
Despite the availability of different antipsychotics for the treatment of schizophrenia, in clinical practice it is somewhat of a struggle to identify an antipsychotic medication for individual patients that they are willing to adhere to. Brexpiprazole is a new molecular entity that is a dopamine receptor partial agonist that differs from aripiprazole in terms of greater potency at serotonin 5-HT1A receptors and less intrinsic activity at dopamine D2 receptors.1 Brexpiprazole received approval in the USA for the treatment of schizophrenia in July 2015......To read the full article, log in using your NHS OpenAthens details
Guest editorial. . MPFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Two £25 vouchers are up for grabs in the library’s ‘Making the Most of Information’ survey.
To take part, just visit http://goo.gl/AdN4ok by Friday 19th February.
Letter. . MPFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
2018 saw a fall in reporting of suspected adverse drug reactions (ADRs) to the Yellow Card Scheme from key reporter groups, including GPs, pharmacists, and hospital doctors. Every Yellow Card report counts, and a few minutes taken by you or your patient to report can make a lifetime of difference for others – don’t delay, report today!
Letter. SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Letter. SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Accumulating evidence suggests an involvement of oxidative stress in the pathophysiology of schizophrenia. This offers a hypothesis-derived therapeutic approach to hinder oxidative damage and its clinical sequelae. α-Lipoic acid (ALA) is a powerful natural antioxidant indicated to treat diabetic neuropathy. SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.